Blood · 2017 · 92 citations · 10 references
Life SciencesPharmacotherapyNeurodegenerationAluminum ToxicityAmyloid FormationProtein Aggregation DisordersAmyloid ToxicityBortezomib-based Therapy
Immunomodulatory drugs are active agents in light-chain (AL) amyloidosis. However, previous studies could not show a survival advantage for patients with AL amyloidosis responding to salvage treatment with pomalidomide. In this phase 2 trial, we assessed the safety and efficacy of pomalidomide and dexamethasone (PDex) in patients with AL amyloidosis who were previously exposed to bortezomib, alkylators, and other immunomodulatory drugs. Twenty-eight patients were enrolled. Three patients received pomalidomide 2 mg/d with no dose-limiting toxicity. The remaining patients received 4 mg/d. Pomalidomide was administered continuously and dexamethasone was given once per week at a dose of 20 or 40 mg. Fifteen patients experienced grade 3 to 4 adverse events; the most common were fluid retention and infection. Hematologic response was observed in 68% of patients (very good partial response or complete response in 29%), as well as improved survival. Median time to response was 1 month. PDex is a rapidly active regimen and improves survival in responding, heavily pretreated patients with AL amyloidosis. This trial was registered at www.clinicaltrials.gov as #NCT01510613.
10
Giovanni Palladini, Angela Dispenzieri, Morie A. Gertz et al. · Journal of Clinical Oncology · 2012 · 969 citations
Medicine, Cardiology, Hematology +17
Giovanni Palladini, Ute Hegenbart, Paolo Milani et al. · Blood · 2014 · 503 citations
Medicine, Nephrology, Oncology +15